News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
Tesaro (TSRO)'s Phase III NOVA Trial of Niraparib Hits Primary Endpoint; NDA and MAA Planned for Q4 2016 6/29/2016
Esperion (ESPR) Falls on Lack of FDA Clarity for Cholesterol Drug 6/29/2016
Center Point Clinical Services Signs Partnership Agreement With ContraVir 6/29/2016
Anthera Provides Clinical Program Updates For Blisibimod And Sollpura 6/29/2016
Omeros (OMER) Announces Completion Of Patient Enrollment In Pediatric Trial Of OMIDRIA 6/29/2016
NeuroDerm (NDRM) Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA In Head-To-Head Pilot PK Comparison Trial 6/29/2016
Investors Gain Focus as Shire (SHPG) Stock Rises at Positive ADHD Drug News 6/29/2016
Infinity Pharma (INFI) Cuts Jobs by 58% as AbbVie (ABBV) Terminates Duvelisib Collaboration Deal 6/28/2016
Celyad’s CHART-1 Phase III Shows No Significant Difference on Primary Endpoint 6/28/2016
BeyondSpring Pharmaceuticals's Global Phase III Non-Small Cell Lung Cancer Clinical Trial For Plinabulin Launches In China 6/28/2016
NewLink Genetics (NLNK) Stock Slides and Company Lays Off 87 After Failed Trial 6/28/2016
AcelRx (ACRX) Completes Patient Enrollment In Remaining Phase 3 Studies Of ARX-04 As A Potential Treatment Of Moderate-To-Severe Acute Pain 6/28/2016
Tobira’s Cenicriviroc Reduces Inflammation And Fibrosis In Animal Models Of Chronic Liver And Kidney Disease Including NASH 6/28/2016
Phase III Data Show Bayer (BAY)'s Stivarga (Regorafenib) Improved Overall Survival In Previously Treated Patients With Unresectable Liver Cancer 6/28/2016
Pfizer (PFE) Release: Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results 6/28/2016
Auris Medical AG (EARS) Completes Enrollment Of Phase 3 TACTT3 Trial With Keyzilen In Acute And Post-Acute Inner Ear Tinnitus 6/28/2016
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6 6/28/2016
VM BioPharma Announces First Patient Dosed In Phase 3 Study Of Gene Therapy Candidate, VM202, In Painful Diabetic Peripheral Neuropathy 6/27/2016
GW Pharma (GWPH)’s Epidiolex Meets Primary Endpoint in Phase III 6/27/2016
The Medicines Company (MDCO) Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE 6/27/2016
Axsome (AXSM) Added To Russell 3000 And Russell 2000 Indexes 6/27/2016
AnGes Terminates Phase III HGF Plasmid, Starts New Plan 6/27/2016
Teva (TEVA) Receives CHMP Positive Opinion For CINQAERO (Reslizumab) 6/24/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
BioCon (BIOCON.NS), Quark Pharmaceuticals Inc. Announce Initiation Of Pivotal Phase II/III Study Of QPI-1007 In Rare Eye Disease In India 6/23/2016
Innocoll (INNL) Announces The Completion Of Enrollment In Two Pivotal Phase III Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections 6/23/2016
Incyte (INCY) Announces First Patient Treated In ECHO-301 Phase 3 Study 6/23/2016
Boston Biomedical Announces First Orphan Drug Designation For Napabucasin In Gastric/GEJ Cancer 6/23/2016
Merrimack (MACK) To Present New Analyses Of Phase 3 NAPOLI-1 Data At The ESMO 18th World Congress On Gastrointestinal Cancer 6/22/2016
Kite Pharma (KITE) and Juno (JUNO)'s R&D Strategy to Reshape Cancer Treatment 6/21/2016
Theravance Biopharma (TBPH) Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study Of The Closed Triple Announced By GlaxoSmithKline (GSK) And Innoviva 6/21/2016
Kiadis Pharma Appoints PCT As Its Contract Manufacturing Organization In The United States 6/21/2016
ABIVAX Release: Analysis Of Ongoing ABX203 Phase IIb/III Trial In Chronic Hepatitis B Virus Infection Shows Good Safety, But Primary Endpoint Of Study Is Unlikely To Be Reached 6/20/2016
Ophthotech Corporation (OPHT) Completes Patient Recruitment In Phase 3 Trial Of Fovista Anti-PDGF Therapy In Combination With Eylea Or Avastin In Wet Age-Related Macular Degeneration 6/20/2016
GlaxoSmithKline (GSK)'s Lung Drug Passes Phase III Test 6/20/2016
Circassia (CIR.L) Stock Crashes as Allergy Drug Flunks Crucial Phase III Study 6/20/2016
Concordia Healthcare Announces PDT With Photofrin Data And Provides Corporate Update 6/20/2016
Allergan (AGN) Release: Data Presented at ASM Microbe Highlight In Vitro Antimicrobial Activity Of AVYCAZ (Ceftazidime And Avibactam) Against Several Species Of Enterobacteriaceae Pathogens And Pseudomonas Aeruginosa, Including Certain Resistant Strains 6/20/2016
Navidea (NAVB) Announces Presentation Of Results Demonstrating Performance Of Lymphoseek In Breast Cancer At SNMMI 6/17/2016
Auris Medical AG (EARS) Initiates ASSENT Phase 3 Trial Of AM-111 For Treatment Of Sudden Deafness 6/17/2016
Stealth Biotherapeutics Reports Positive Elamipretide Data In First-Of-Its-Kind Primary Mitochondrial Myopathy Trial 6/17/2016
Medgenics, Inc. Announces Enrollment Of First Patient In Phase 2/3 Clinical Trial Of NFC-1 In Adolescents With mGluR Mutation Positive ADHD 6/17/2016
Pfizer (PFE) Head of R&D Talks Strategy on How Pharma Chooses Compounds to Bet A Billion Dollars On 6/16/2016
Aerie (AERI) Completes Enrollment Of Rocket 4 Phase III Clinical Trial Of Rhopressatm (Netarsudil Ophthalmic Solution) 0.02% 6/16/2016
Can-Fite BioPharma (CFBI) Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects 6/16/2016
ContraVir Expands Patient Enrollment Criteria For Ongoing Phase III Clinical Study Of FV-100 For Treating Shingles 6/16/2016
Braeburn Pharma Release: Probuphine (buprenorphine) Implant Phase 3 Data Presented At CPDD Annual Scientific Meeting 6/16/2016
Merck & Co. (MRK) Soars as Keytruda Impresses in Late-Stage Lung Cancer Study 6/16/2016
Celator Pharma (CPXX) Announces Positive Results In Patients With FLT3 Mutation From The Phase 3 Trial In High-Risk Acute Myeloid Leukemia 6/15/2016
Jazz Pharma (JAZZ) Presents New Data From A Human Abuse Liability (HAL) Study For JZP-110, An Investigational Treatment For Excessive Sleepiness In Patients With Narcolepsy Or With Obstructive Sleep Apnea, At 30th Annual SLEEP Meeting 6/15/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Thymosin Beta 4 Effective In Treatment Of Heart Attack Patients 6/15/2016
Novo Nordisk A/S (NVO) Release: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In Hba1c In Type 1 Diabetes And A Comparable Hba1c Reduction In Type 2 Diabetes Versus Novolog® (Insulin Aspart [rDNA Origin] Injection) 6/14/2016
IBSA Release: Prescription Chondroitin Sulphate Is As Efficacious As Celecoxib And Better Than Placebo In Knee Osteoarthritis 6/14/2016
Novo Nordisk Canada Inc. (NVO) Release: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In Hba(1c) In Type 1 Diabetes And A Comparable HbA(1c) Reduction In Type 2 Diabetes Versus NovoRapid (Insulin Aspart) 6/14/2016
Amgen (AMGN) Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab 6/14/2016
Once Floated as Allergan (AGN) Target, Revance (RVNC)'s Stock Drops as Crow’s Feet Drug Fails Trial 6/14/2016
Sanofi (SNY)'s New Diabetes Combo Nails Late-Stage Goals 6/13/2016
SymBio Pharma Release: Initiation Of Phase III Clinical Trial On The Patient-Controlled Pain Management Drug "SyB P-1501" 6/13/2016
Catalyst Pharma (CPRX) Announces Agreement With FDA On Confirmatory Phase III Study Protocol For Firdapse In Lambert-Eaton Myasthenic Syndrome 6/13/2016
Dynavax (DVAX) Presents New Efficacy Data On Hepatitis B Vaccine, HEPLISAV-B, In Adults With Type 2 Diabetes At American Diabetes Association Scientific Sessions 6/13/2016
Marinus Pharma (MRNS)'s Stock Plummets as Seizure Drug Flunks Phase III Study 6/13/2016
Merck & Co. (MRK)’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint In Two Phase III Studies, Showing Non-Inferiority To Lantus 6/13/2016
REPEAT/Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Amgen (AMGN) Release: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression 6/13/2016
Pfizer (PFE) Announces Final Results From Inotuzumab Ozogamicin Pivotal Phase III Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia 6/13/2016
Seattle Genetics (SGEN) Highlights Vadastuximab Talirine (SGN-CD33A) Data In Acute Myeloid Leukemia (AML) At The 21st Congress Of European Hematology Association 6/13/2016
Merck & Co. (MRK) An Pfizer (PFE) Announce Two Pivotal Phase III Studies For Ertugliflozin, An Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions In Patients With Type 2 Diabetes 6/13/2016
AstraZeneca PLC (AZN) Presents Findings From Two Pooled Analyses At The 76th Scientific Sessions Of The American Diabetes Association Evaluating Dapagliflozin In Type 2 Diabetes Patients With Renal Impairment And In Combination With Potassium-Sparing Agents 6/13/2016
Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Novo Nordisk A/S (NVO) Release: Tresiba (Insulin Degludec Injection U-100) Demonstrated Significantly Lower Rates Of Overall, Nocturnal And Severe Hypoglycaemia Vs Insulin Glargine U-100 6/13/2016
Janssen Pharmaceutical Presents New Data Showing Invokana (Canagliflozin) Is Associated With Greater Blood Glucose Control And Treatment Adherence Compared To Dpp-4 Inhibitors 6/13/2016
Intarcia Presents FREEDOM-2 Trial Results In Type 2 Diabetes Demonstrating Clinically Meaningful Superiority And Sustained Glucose Control And Weight Reduction For ITCA 650 Vs. Januvia: Oral Presentation At American Diabetes Association 76th Scientific Sessions 6/13/2016
Novo Nordisk A/S (NVO) Release: Semaglutide Demonstrated Superior Improvements In Glycaemic Control Vs Sitagliptin (SUSTAIN 2) And Exenatide ER (SUSTAIN 3) In Two Clinical Trials In Adults With Type 2 Diabetes 6/13/2016
Intarcia Release: New NHANES Analysis Shows No Improvement In Last Decade To Get More Diabetes Patients To Hba1c Goal; Separate Study Suggests Reduced Efficacy In Real-World Plays Large Role Due To Adherence Falling Far Short Of Clinical Trials 6/13/2016
Eli Lilly (LLY) Release: New Data Show Eli Lilly (LLY)'s Once-Weekly Trulicity (Dulaglutide) In Combination With Insulin Glargine Improves Glycemic Control In People With Type 2 Diabetes 6/13/2016
ProMetic Life Sci (PFSCF.PK)'s Plasminogen Granted Fast Track Designation By FDA 6/13/2016
Prothena (PRTA) Presents First Clinical Data for PRX003 for the Treatment of Inflammatory Diseases 6/10/2016
Incyte (INCY) Release: New Phase III Data Show Jakafi (Ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV) 6/10/2016
Janssen-Cilag International NV (JNJ) Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma 6/10/2016
Amgen (AMGN) Release: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia 6/10/2016
Janssen R&D Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma 6/10/2016
PTC Therapeutics (PTCT) Release: New Analyses From Phase 3 Study 009 Of Translarna (Ataluren) In Patients With Cystic Fibrosis Presented At 39th European Cystic Fibrosis Conference 6/10/2016
AVANIR (AVNR) To Present Data On ONZETRA Xsail At American Headache Society (AHS) 2016 Annual Scientific Meeting 6/10/2016
Vertex (VRTX) Announces Presentations Of Data For KALYDECO (Ivacaftor) And ORKAMBI® (Lumacaftor/Ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference 6/10/2016
New Data Presented At The Annual European Congress Of Rheumatology (EULAR 2016) Demonstrate Safety And Efficacy Of Biogen (BIIB)’s Anti-TNF Biosimilars Portfolio 6/9/2016
ASCO2016: ProvectusAnnounces Poster Presentation On PV-10 At Annual Meeting Of American Society Of Clinical Oncology Now Available Online 6/9/2016
Eli Lilly (LLY) Release: Patient-Reported Outcomes Across Phase 3 Studies Of Baricitinib Demonstrate Statistically Significant Improvements In Physical Function And Quality Of Life Symptoms In Patients With Rheumatoid Arthritis (RA) 6/9/2016
Studies Demonstrate Eli Lilly (LLY)'s Taltz (Ixekizumab) Maintained Or Achieved High Levels Of Skin Clearance For Patients With Moderate-To-Severe Plaque Psoriasis Through 60 Weeks: Results Published In The New England Journal of Medicine 6/9/2016
Eli Lilly (LLY) Release: Baricitinib Significantly Reduces Joint Damage Progression In Rheumatoid Arthritis In Patients Who Do Not Respond To Conventional DMARDs 6/9/2016
AVANIR (AVNR) Release: NUEDEXTA Effective For Pseudobulbar Affect (PBA) In Patients With Alzheimer's Disease And Other Dementias, Stroke And Traumatic Brain Injury 6/9/2016
Bristol-Myers Squibb Canada (BMY) Release: Canada's Health Technology Assessment Agency Gives Positive Recommendation For OPDIVO To Treat Non-Small Cell Lung Cancer 6/9/2016
Mast Therapeutics (MSTX) Receives Notice Of Allowance Of Composition Of Matter Patent Application Covering Vepoloxamer 6/9/2016
GlaxoSmithKline (GSK), Johnson & Johnson (JNJ)'s Rheumatoid Arthritis Drug Meets Goals in Large Late-Stage Study 6/8/2016
New Janssen R&D Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease 6/8/2016
Trevena (TRVN) Announces First Patients Enrolled In The APOLLO-1 And APOLLO-2 Phase III Pivotal Efficacy Studies Of Oliceridine In Acute Pain 6/8/2016
Remedy Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CIRARA 6/8/2016
Samsung Bioepis Announces New Data On Three Anti-TNF--a Biosimilar Molecules At The Annual European Congress On Rheumatology (EULAR 2016) 6/8/2016
CoLucid Pharma (CLCD) Completes Enrollment for SAMURAI Phase III Study Evaluating Oral Lasmiditan 6/8/2016
Pfizer (PFE)'s Xeljanz Successful in Second Phase III Psoriatic Arthritis Study 6/7/2016
ASCO2016: Array BioPharma (ARRY) Presents Full Results From Phase 3 NEMO Study 6/7/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Treats First Patient In ICT-107 Phase 3 Registrational Trial In Newly Diagnosed Glioblastoma 6/7/2016
Can-Fite BioPharma (CFBI) Submits Psoriasis Phase III Protocol And Registration Plan To European Medicines Agency For Piclidenoson (CF101) 6/7/2016
PARI Pharma's Investigational Closed eFlow Nebulizer System Used In Two Successful Phase 3 Clinical Studies Evaluating Sunovion Pharmaceuticals Inc.'s SUN-101 (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 6/7/2016
ASCO2016: Amgen (AMGN) Release: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen 6/7/2016
Cytori Therapeutics (CYTX) Announces Enrollment Completion In U.S. Phase III Scleroderma Trial 6/7/2016
ASCO2016: AEterna Zentaris (AEZS) Reconfirms Commitment To LHRH-Receptor Targeting Zoptrex During 2016 ASCO Annual Meeting 6/7/2016
ASCO2016: Novartis Pharmaceuticals Corporation (NVS) Combination Therapy Tafinlar + Mekinist Demonstrates Overall Survival Benefit At Three-Year Follow-Up In Patients With Advanced Melanoma 6/7/2016
Regeneron (REGN) and Sanofi (SNY)'s Dermatitis Drug Meets Goals in Late-Stage Study 6/6/2016
Ocular Therapeutix (OCUL)'s Pink Eye Treatment Dextenza Flunks Phase III Test 6/6/2016
ASCO2016: Exelixis (EXEL) And Its Partner Ipsen (IPN.PA) Announce Positive Overall Survival Results From Subgroup Analyses Of Phase III Trial Of CABOMETYX (Cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting 6/6/2016
Highland Therapeutics Announces Positive Data From Second Pivotal ADHD Trial For HLD-200 6/6/2016
Genentech (RHHBY)'s Arthritis Med Actemra Successful In Late-Stage Study in Rare Artery Inflammation 6/6/2016
Ipsen (IPN.PA) Release: Endocrine Practice Publishes ELECT Phase III Trial Results In Adults With Carcinoid Syndrome 6/6/2016
ASCO2016: Incyte (INCY) Release: Five-Year Results From Phase III Study Of Jakafi (Ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF) 6/6/2016
ASCO2016: Ariad (ARIA)'s Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate And 12.9-Month Median Progression-Free Survival In ALTA Study 6/6/2016
ASCO2016: Mylan (MYL)-BioCon (BIOCON.NS)'s Biosimilar Cancer Drug Comparable to Roche (RHHBY)'s Herceptin 6/6/2016
Frontier Biotech's Long-Acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results Of A Phase 3 Trial 6/6/2016
ASCO2016: Celator Pharma (CPXX) Presented Phase 3 Trial Results In Patients With High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS (CPX-351) Significantly Improved Overall Survival 6/6/2016
ASCO2016: SELLAS Life Sciences Group Announces Exciting Results For Galinpepimut-S, The Company's WT1 Vaccine, In Patients With Acute Myeloid Leukemia (AML) And Malignant Pleural Mesothelioma (MPM), As Presented At The 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: AbbVie (ABBV) Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeting 6/6/2016
Merck & Co. (MRK) Partners With Array BioPharma (ARRY) And Pierre Fabre To Initiate BRAF-Mutant CRC Phase III Trial 6/6/2016
ASCO2016: OBI Pharma (SHPG) Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
ASCO2016: Janssen R&D Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma 6/6/2016
Array BioPharma (ARRY), Pierre Fabre And Merck KGaA (MKGAF.PK), Darmstadt, Germany Announce Phase 3 BEACON CRC Trial 6/6/2016
Janssen Expands Body Of Evidence For INVOKANA (Canagliflozin) With 18 New Data Presentations At American Diabetes Association's 76th Scientific Sessions 6/6/2016
CVRx, Inc. Announces That The First Two Patients Were Treated In The Phase III Pivotal Trial Evaluating BAROSTIM THERAPY For The Treatment Of Heart Failure 6/6/2016
Long-Term Data From Two Trials Evaluating The Opdivo (Nivolumab) And Yervoy (Ipilimumab) Regimen In Advanced Melanoma Continues To Validate Bristol-Myers Squibb (BMY)’s Immuno-Oncology Combination Approach 6/6/2016
ASCO2016: IntegraGen, Inc. Presents Positive Data At 2016 ASCO Meeting On The Role Of Microrna Biomarker miR-31-3p In Patients With Metastatic Colorectal Cancer Enrolled In FIRE-3 Clinical Trial 6/6/2016
ASCO2016: AstraZeneca PLC (AZN) LYNPARZA (Olaparib): Latest Data Suggest Potential Overall Survival Advantage In Patients With Platinum Sensitive Ovarian Cancer 6/6/2016
Novo Nordisk A/S (NVO) To Present 53 Abstracts At 76th Annual American Diabetes Association Scientific Sessions In New Orleans, LA 6/6/2016
Axovant (AXON) Announces 2015 Fiscal Year-End Financial Results And Corporate Updates 6/6/2016
ASCO2016: Janssen Pharmaceutical Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma 6/6/2016
Polaris Group Reports Phase III Study Results Of ADI-PEG 20 Plus Best Supportive Care In Advanced Hepatocellular Carcinoma 6/6/2016
ASCO2016: Celgene (CELG) Pooled Data From Meta-Analysis Suggest Significant Overall Survival Benefit Of Investigational REVLIMID Maintenance Following Autologous Stem Cell Transplant In Multiple Myeloma 6/6/2016
ASCO2016: AbbVie (ABBV) Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeting 6/6/2016
Alexion (ALXN) Announces Topline Results From Phase III REGAIN Study Of Eculizumab (Soliris®) In Patients With Refractory Generalized Myasthenia Gravis (gMG) 6/6/2016
Phase III Study Shows Genentech (RHHBY)’s Actemra (Tocilizumab) Maintained Steroid-Free Remission In People With Giant Cell Arteritis (GCA) 6/6/2016
Bayer (BAY) And Orion Corporation Expand Clinical Development Program For BAY-1841788 (ODM-201) In Prostate Cancer 6/3/2016
Nektar Therapeutics (NKTR)' President And CEO, Howard W. Robin, To Present At The Jefferies 2016 Global Healthcare Conference In New York City 6/3/2016
Dermira (DERM) Jumps as Excessive Armpit Sweating Drug Succeeds in Late-Stage Studies 6/2/2016
Peregrine (PPHM) Nixes Planned Trials for Bavituximab, But Hints at a Future Trial with AstraZeneca PLC (AZN)’s Durvalumab 6/2/2016
Astellas (ALPMY) And Medivation (MDVN) Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer 6/2/2016
Genmab A/S (GEN.CO) Announces Phase III Studies Of Ofatumumab In Relapsing Multiple Sclerosis 6/2/2016
BIO2016: ContraVir To Present At 2016 Biotechnology Innovation Organization International Convention 6/2/2016
BIO2016: Resverlogix (RVX.TO) Announces Lead Drug Apabetalone Publication And Presentation At BIO International 2016 6/2/2016
Achaogen (AKAO) Reaches 50 Percent Patient Enrollment In Phase 3 EPIC Registration Trial Of Plazomicin 6/2/2016
AbbVie (ABBV)'s Research And Commitment To Helping People Living With Rheumatologic Diseases Highlighted At The Annual European Congress Of Rheumatology (EULAR 2016) 6/2/2016
Boehringer Ingelheim Launches Ambitious ELUXA Trial Programme To Broadly Investigate Promising Lung Cancer Compound Olmutinib 6/2/2016
Theravance Biopharma (TBPH) Completes Enrollment In All Three Phase 3 Clinical Studies Of Revefenacin (TD-4208) For Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 6/2/2016
Nektar Therapeutics (NKTR), DAIICHI SANKYO EUROPE GmbH Strike $80 Million+ ONZEALD Pact 6/1/2016
Can-Fite BioPharma (CFBI) Reaches Agreement With European Medicines Agency On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis 6/1/2016
Regulus (RGLS) Expands Clinical Trial Collaboration With GlaxoSmithKline (GSK) 6/1/2016
PharmaEngine, Inc. Announces Initiation Of Global Pivotal Trial Of PEP503 (NBTXR3) In Soft Tissue Sarcoma In Asia Pacific Region 6/1/2016
Bayer (BAY) Collaborates With U.S. National Surgical Adjuvant Breast And Bowel Project (NSABP) To Investigate Stivarga (Regorafenib) Tablets As Additional Adjuvant Therapy In Colon Cancer 6/1/2016
Lipidor And Cadila Pharmaceuticals Announce Agreement On Phase III Clinical Study And Joint Commercialization Of Topical Psoriasis Product 6/1/2016
Helsinn Group To Present At ASCO Pooled Follow Up Efficacy Data Analysis From Two Phase III Studies For Anamorelin In Cachectic Patients With Non-Small Cell Lung Cancer (NSCLC) 6/1/2016
Biogen (BIIB)’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted Into European Medicines Agency’s PRIME Program 6/1/2016
CEL-SCI (CVM) Reports Monthly Patient Enrollment In May For Its Phase III Head And Neck Cancer Trial 6/1/2016
ASCO2016: Helsinn Group To Present At ASCOPooled Follow Up Efficacy Data Analysis From Two Phase III Studies For Anamorelin In Cachectic Patients With Non-Small Cell Lung Cancer (NSCLC) 6/1/2016
Novo Nordisk A/S (NVO) Release: Semaglutide Demonstrated Superior Glycemic Control Vs Insulin Glargine U100 In Adults With Type 2 Diabetes 5/31/2016
ContraVir To Expand Hepatitis B Portfolio Through Strategic Merger Agreement With Ciclofilin Pharmaceuticals 5/31/2016
ASCO2016: SillaJen Announces Poster Presentation At ASCO Annual Meeting 5/31/2016
ASCO2016: TRANSGENE (ENX:TNG) Announces Poster Presentation At ASCO Annual Meeting On The Phase 3 PHOCUS Clinical Trial With Pexa-Vec Oncolytic Immunotherapy 5/31/2016
CEL-SCI (CVM) To Present At The Fifth Annual Marcum MicroCap Conference 5/31/2016
Daiichi Sankyo, Inc. (DSNKY) Not Proceed With Lung Cancer Study 5/31/2016
Novartis AG (NVS) Trial Stopped Early on Positive Data, Gets Ready to Take on Pfizer (PFE)'s Ibrance 5/31/2016
Genentech (RHHBY)’s Gazyva Meets Primary Endpoint Early in Late-Stage Study 5/27/2016
AstraZeneca PLC (AZN)'s Fulvestrant Meets Goals in Phase III Study 5/27/2016
Ionis Pharma (IONS) Plummets After GlaxoSmithKline (GSK) Opts Not to Initiate Phase III Study for Amyloid Cardiomyopathy Drug 5/27/2016
Amgen (AMGN) Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 5/27/2016
Amgen (AMGN) Release: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" 5/27/2016
Portola (PTLA) Announces Full Results Of Phase 3 APEX Study Of Betrixaban Presented At International Society On Thrombosis And Haemostasis (ISTH) Meeting 5/27/2016
The Medicines Company (MDCO) Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE (Meropenem-Vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI) 5/27/2016
ASCO Selects BeyondSpring Abstract On Neutropenia Mitigation With Plinabulin Use For Publication 5/27/2016
Pfizer (PFE)'s Quest to Become a Cancer Powerhouse 5/26/2016
AcelRx (ACRX) Presents Results From Phase 3 Study Of ARX-04 Following Ambulatory Abdominal Surgeries At Euroanaesthesia 5/26/2016
Symbiomix Announces Positive Results From Phase 3 Trial Of SYM-1219 For Bacterial Vaginosis, And Pre-NDA Meeting With FDA Supportive Of 2016 NDA Filing 5/26/2016
AVEO Oncology (AVEO) Announces Dosing Of First Patient In The Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma 5/26/2016
Acucela Announces Top-Line Results From Phase 2b/3 Clinical Trial Of Emixustat 5/26/2016
Eli Lilly (LLY) Projects 20 New Product Launches in 10 Years with 20 Possible Expansions 5/25/2016
Innocoll (INNL)'s Painkiller Passes Final Phase III Tests, Heads for 2017 Launch 5/25/2016
FDA Grants Fast Track Designation To Novavax (NVAX)’ RSV F Vaccine For Older Adults 5/25/2016
Synergy Pharma Presents New In Vitro Data Showing The pH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin 5/25/2016
Seattle Genetics (SGEN) Initiates Pivotal Phase III Trial Of Vadastuximab Talirine (SGN-CD33A) For Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) 5/25/2016
Cytori Therapeutics (CYTX) Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial 5/25/2016
Synergy Pharma Presents New In Vitro Data Showing The pH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin 5/24/2016
Theratechnologies (TH.TO) Says 82.5% of Patients Achieved Primary Endpoint in Phase III Ibalizumab Trial 5/24/2016
After Initial Miss, GlaxoSmithKline (GSK)'s Pioneering Lung Study Shows Positive Results 5/24/2016
Janssen R&D Release: New Phase 3 Study Findings Show STELARA Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn's Disease 5/24/2016
SELLAS Life Sciences Group Announces Upcoming Presentation Of Phase 2 Clinical Results For WT1 Cancer Vaccine At The 2016 ASCO Annual Meeting 5/24/2016
Celsion (CLSN) Announces Presentation Of OVATION Study Clinical Trial Design At Upcoming ASCO 2016 Meeting 5/24/2016
Eisai Inc. (ESALF.PK) To Present Analyses At 2016 ASCO Annual Meeting From Trials Supporting Recent FDA Approvals For The Company's Oncology Therapies 5/24/2016
Xbiotech To Present Positive Preliminary Survival Data On Xilonix At The 18th European Society Of Medical Oncology’s World Congress On Gastrointestinal Cancer 5/24/2016
Shionogi Release: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation 5/24/2016
Cytel Breaks New Ground In Adaptive Designs With East 6.4 Release 5/24/2016
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2016
Norgine Release: New Positive Phase III Study For NER1006 - The First 1 Litre PEG-Based Bowel Preparation 5/24/2016
Vtesse Advances Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease With Dose Selection For Evaluation In Second And Final Portion Of Trial And Expansion Into Europe 5/23/2016
Mast Therapeutics (MSTX) Release: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At European Society of Cardiology 3rd World Congress On Acute Heart Failure 5/23/2016
AlloSource Distributes First Bioengineered Blood Vessels For Humacyte Phase III Clinical Trial 5/23/2016